Alx Oncology Holdings (ALXO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alx Oncology Holdings (ALXO) has a cash flow conversion efficiency ratio of -0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.65 Million) by net assets ($151.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alx Oncology Holdings (ALXO) defensive interval to measure how many days the company can operate on defensive assets alone.
Alx Oncology Holdings - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alx Oncology Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alx Oncology Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smart Sand Inc
NASDAQ:SND
|
0.093x |
|
China Rare Earth Holdings Limited
F:RAE
|
-0.063x |
|
JINSUNG T.E.C. Inc
KQ:036890
|
-0.016x |
|
TRG Latin America Acquisitions Corp. Class A Ordinary Shares
NASDAQ:TRGS
|
-0.002x |
|
Bank Amar Indonesia
JK:AMAR
|
0.022x |
|
HomeChoice Investments Ltd
JSE:HIL
|
-0.138x |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
-0.111x |
|
Taisol Electronics Co Ltd
TW:3338
|
0.071x |
Annual Cash Flow Conversion Efficiency for Alx Oncology Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Alx Oncology Holdings from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Alx Oncology Holdings market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $25.98 Million | $-84.14 Million | -3.239x | -201.83% |
| 2024-12-31 | $113.62 Million | $-121.91 Million | -1.073x | -56.15% |
| 2023-12-31 | $189.71 Million | $-130.36 Million | -0.687x | -102.91% |
| 2022-12-31 | $263.46 Million | $-89.22 Million | -0.339x | -80.54% |
| 2021-12-31 | $363.05 Million | $-68.10 Million | -0.188x | -110.58% |
| 2020-12-31 | $429.85 Million | $-38.29 Million | -0.089x | -100.17% |
| 2019-12-31 | $-276.00K | $-14.25 Million | 51.627x | +3683.35% |
| 2018-12-31 | $9.15 Million | $-13.19 Million | -1.441x | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more